Cleveland Clinic study: timing of melanoma diagnosis, treatment critical to survival

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

FDA approved an Investigational Device Exemption application to initiate a multi-center study for the treatment of recurrent cutaneous squamous cell carcinoma in immunocompromised patients using the Alpha DaRT.

October 11, 2024

Vol.50 No.38

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

September 27, 2024

Vol.50 No.36

Regulatory News

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Follow-up data from the phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with Keytruda in patients with resected high-risk melanoma (stage 3/4) following complete resection.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Ten-year follow-up data from CheckMate-067, a randomized, double-blind, phase III clinical trial showed continued durable improvement in survival with first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untreated advanced or metastatic melanoma.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Dysfunctional white blood cells linked to heightened melanoma risk

Mayo Clinic study has found that 8 million to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition—called monoclonal B-cell lymphocytosis—do not experience any symptoms, a recent study shows they may have an elevated risk for several health complications, including melanoma.

September 13, 2024

Vol.50 No.34

Cleveland Clinic study: timing of melanoma diagnosis, treatment critical to survival

YOU MAY BE INTERESTED IN

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Dysfunctional white blood cells linked to heightened melanoma risk

Renew today!

Subscriber content

Never miss an issue!

Login

Cleveland Clinic study: timing of melanoma diagnosis, treatment critical to survival

YOU MAY BE INTERESTED IN

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover designThe agency accepts the invitation

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Dysfunctional white blood cells linked to heightened melanoma risk

Never miss an issue!

Login

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation